Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 2860956, 7 pages
https://doi.org/10.1155/2017/2860956
Research Article

Epac1 Blocks NLRP3 Inflammasome to Reduce IL-1β in Retinal Endothelial Cells and Mouse Retinal Vasculature

1Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, MI, USA
2Department of Ophthalmology, Wayne State University School of Medicine, Detroit, MI, USA

Correspondence should be addressed to Jena J. Steinle; ude.enyaw.dem@elnietsj

Received 1 November 2016; Revised 24 January 2017; Accepted 5 February 2017; Published 28 February 2017

Academic Editor: Ulrich Eisel

Copyright © 2017 Youde Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Tang and T. S. Kern, “Inflammation in diabetic retinopathy,” Progress in Retinal and Eye Research, vol. 30, no. 5, pp. 343–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. T. S. Kern, “Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy,” Experimental diabetes research, vol. 2007, Article ID 95103, 2007. View at Google Scholar · View at Scopus
  3. L. Zheng, Y. Du, C. Miller et al., “Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes,” Diabetologia, vol. 50, no. 9, pp. 1987–1996, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. F. Abcouwer, C.-M. Lin, S. Shanmugam, A. Muthusamy, A. J. Barber, and D. A. Antonetti, “Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury,” Journal of Neuroinflammation, vol. 10, article 149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Vincent and S. Mohr, “Inhibition of caspase-1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia,” Diabetes, vol. 56, no. 1, pp. 224–230, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. De Nardo and E. Latz, “NLRP3 inflammasomes link inflammation and metabolic disease,” Trends in Immunology, vol. 32, no. 8, pp. 373–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. R. W. Grant and V. D. Dixit, “Mechanisms of disease: inflammasome activation and the development of type 2 diabetes,” Frontiers in Immunology, vol. 4, article 50, 2013. View at Publisher · View at Google Scholar
  8. S. K. Vanaja, V. A. K. Rathinam, and K. A. Fitzgerald, “Mechanisms of inflammasome activation: recent advances and novel insights,” Trends in Cell Biology, vol. 25, no. 5, pp. 308–315, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. I. N. Mohamed, T. Ishrat, S. C. Fagan, and A. B. El-Remessy, “Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit,” Antioxidants and Redox Signaling, vol. 22, no. 13, pp. 1188–1206, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Chi, H. Chen, F. Li, Y. Zhu, W. Yin, and Y. Zhuo, “HMGB1 promotes the activation of NLRP3 and caspase-8 inflammasomes via NF-κB pathway in acute glaucoma,” Journal of Neuroinflammation, vol. 12, no. 1, article 137, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Wang, J. W. Hanus, M. S. Abu-Asab et al., “NLRP3 upregulation in retinal pigment epithelium in age-related macular degeneration,” International Journal of Molecular Sciences, vol. 17, no. 1, article 73, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Shi, Z. Zhang, X. Wang et al., “Inhibition of autophagy induces IL-1β release from ARPE-19 cells via ROS mediated NLRP3 inflammasome activation under high glucose stress,” Biochemical and Biophysical Research Communications, vol. 463, no. 4, pp. 1071–1076, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. E. A. Berger, T. W. Carion, Y. Jiang et al., “β-Adrenergic receptor agonist, compound 49b, inhibits TLR4 signaling pathway in diabetic retina,” Immunology and Cell Biology, vol. 94, no. 7, pp. 656–661, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Whitaker and N. G. F. Cooper, “Differential distribution of exchange proteins directly activated by cyclic AMP within the adult rat retina,” Neuroscience, vol. 165, no. 3, pp. 955–967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Jiang, L. Liu, and J. J. Steinle, “Compound 49b regulates ZO-1 and occludin levels in human retinal endothelial cells and in mouse retinal vasculature,” Investigative Opthalmology & Visual Science, vol. 58, no. 1, pp. 185–189, 2017. View at Publisher · View at Google Scholar
  16. E.-Y. Moon, J.-H. Lee, J.-W. Lee, J.-H. Song, and S. Pyo, “ROS/Epac1-mediated Rap1/NF-kappaB activation is required for the expression of BAFF in Raw264.7 murine macrophages,” Cellular Signalling, vol. 23, no. 9, pp. 1479–1488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. E.-Y. Moon, Y.-S. Lee, W. S. Choi, and M.-H. Lee, “Toll-like receptor 4-mediated cAMP production up-regulates B-cell activating factor expression in Raw264.7 macrophages,” Experimental Cell Research, vol. 317, no. 17, pp. 2447–2455, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Van Beijnum, W. A. Buurman, and A. W. Griffioen, “Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1),” Angiogenesis, vol. 11, no. 1, pp. 91–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Tsung, S. Tohme, and T. R. Billiar, “High-mobility group box-1 in sterile inflammation,” Journal of Internal Medicine, vol. 276, no. 5, pp. 425–443, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002. View at Google Scholar · View at Scopus
  21. T. S. Kern and R. L. Engerman, “Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin,” Diabetes, vol. 50, no. 7, pp. 1636–1642, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. D. M. McDonald, G. Coleman, A. Bhatwadekar, T. A. Gardiner, and A. W. Stitt, “Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction,” Molecular Vision, vol. 15, pp. 1509–1520, 2009. View at Google Scholar · View at Scopus
  23. T. A. Gardiner, H. R. Anderson, and A. W. Stitt, “Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes,” Journal of Pathology, vol. 201, no. 2, pp. 328–333, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. U. Andersson and K. J. Tracey, “HMGB1 is a therapeutic target for sterile inflammation and infection,” Annual Review of Immunology, vol. 29, pp. 139–162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, “Thioredoxin-interacting protein links oxidative stress to inflammasome activation,” Nature Immunology, vol. 11, no. 2, pp. 136–140, 2010. View at Publisher · View at Google Scholar · View at Scopus